Skip to main content
Top
Published in: Infectious Diseases and Therapy 3/2017

Open Access 01-09-2017 | Original Research

In vitro and In vivo Activity of Theaflavin–Epicatechin Combinations versus Multidrug-Resistant Acinetobacter baumannii

Authors: Jonathan W. Betts, Michael Hornsey, David W. Wareham, Roberto M. La Ragione

Published in: Infectious Diseases and Therapy | Issue 3/2017

Login to get access

Abstract

Introduction

Acinetobacter baumannii is an important human nosocomial pathogen; most clinical isolates are multidrug-resistant (MDR). Infections caused by A. baumannii often lead to high morbidity and mortality, with limited treatment options. Owing to the small number of anti-Gram-negative antibiotics in the development pipeline, researchers are looking to other natural compounds. The aim of this study was to determine the in vitro kill kinetics, in vivo efficacy and toxicity of theaflavin–epicatechin combinations against MDR A. baumannii.

Methods

Kill-kinetic assays were performed in Mueller–Hinton 2 broth over 24 h. Toxicity of the compound in the insect model, Galleria mellonella was investigated. The effect of theaflavin–epicatechin combinations on mortality and morbidity were assessed in Acinetobacter baumannii-infected G. mellonella. Larvae were scored for morbidity (melanisation: scale; 0–4) and mortality over 96 h.

Results

Kill-kinetic assays revealed that monotherapy had bacteriostatic activity over 24 h, whereas theaflavin–epicatechin combinations were bactericidal (a >3 log reduction in bacterial numbers at 24 h compared with the starting inoculum). Both polyphenols were non-toxic to G. mellonella at concentrations of up to 1000 mg/kg. In vivo treatment assays showed that the combination significantly increased (t test; p ≤ 0.05) larval survival at 96 h to 86% [±17 standard deviation percentage points (pp)] compared to monotherapy with theaflavin (52% ± 14 pp), epicatechin (44% ± 25 pp) or PBS (31% ± 13 pp). Morbidity was also lower in larvae treated with the combination, compared with monotherapy.

Conclusion

Polyphenol combinations produce effective antibacterial action against A. baumannii and show great potential for the treatment of infections caused by MDR A. baumannii.
Literature
1.
go back to reference Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079–81.CrossRefPubMed Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079–81.CrossRefPubMed
3.
go back to reference Phee LM, Betts JW, Bharathan B, Wareham DW. Colistin and fusidic acid, a novel potent synergistic combination for treatment of multidrug-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2015;59(8):4544–50.CrossRefPubMedPubMedCentral Phee LM, Betts JW, Bharathan B, Wareham DW. Colistin and fusidic acid, a novel potent synergistic combination for treatment of multidrug-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2015;59(8):4544–50.CrossRefPubMedPubMedCentral
5.
go back to reference Steinmann J, Buer J, Pietschmann T, Steinmann E. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol. 2013;168(5):1059–73.CrossRefPubMedPubMedCentral Steinmann J, Buer J, Pietschmann T, Steinmann E. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol. 2013;168(5):1059–73.CrossRefPubMedPubMedCentral
6.
go back to reference Cho YS, Schiller NL, Oh KH. Antibacterial effects of green tea polyphenols on clinical isolates of methicillin-resistant Staphylococcus aureus. Curr Microbiol. 2008;57:542–6.CrossRefPubMed Cho YS, Schiller NL, Oh KH. Antibacterial effects of green tea polyphenols on clinical isolates of methicillin-resistant Staphylococcus aureus. Curr Microbiol. 2008;57:542–6.CrossRefPubMed
7.
go back to reference Friedmann M, Henika PR, Levin CE, Mandrill RE, Kozukue N. Antimicrobial activities of tea catechins and theaflavins and tea extracts against Bacillus cereus. J Food Prot. 2006;69(2):354–61.CrossRef Friedmann M, Henika PR, Levin CE, Mandrill RE, Kozukue N. Antimicrobial activities of tea catechins and theaflavins and tea extracts against Bacillus cereus. J Food Prot. 2006;69(2):354–61.CrossRef
8.
go back to reference Park BJ, Park JC, Taguchi H, Fukushima K, Hyon SH. Antifungal susceptibility of epigallocatechin-3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts. Biochem Biophys Res Comm. 2006;347(2):401–5.CrossRefPubMed Park BJ, Park JC, Taguchi H, Fukushima K, Hyon SH. Antifungal susceptibility of epigallocatechin-3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts. Biochem Biophys Res Comm. 2006;347(2):401–5.CrossRefPubMed
9.
go back to reference Lee S, Al Razqan GS, Kwon DH. Antibacterial activity of epicatechin-3-gallate (EGCG) and its synergism with β-lactam antibiotics sensitize carbapenem-associated multidrug-resistant clinical isolates of Acinetobacter baumannii. Phytomedicine. 2017;24:49–55.CrossRefPubMed Lee S, Al Razqan GS, Kwon DH. Antibacterial activity of epicatechin-3-gallate (EGCG) and its synergism with β-lactam antibiotics sensitize carbapenem-associated multidrug-resistant clinical isolates of Acinetobacter baumannii. Phytomedicine. 2017;24:49–55.CrossRefPubMed
10.
go back to reference Cui Y, Kim SH, Kin H, Yeom J, Ko K, Park W, Park S. AFM probing the mechanism of synergistic effects of the green tea polyphenol (−)epigallocatechin-3-gallate (EGCG) with cefotaxime against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli. PLoS ONE. 2012. doi:10.1371/journal.pone.0048880. Cui Y, Kim SH, Kin H, Yeom J, Ko K, Park W, Park S. AFM probing the mechanism of synergistic effects of the green tea polyphenol (−)epigallocatechin-3-gallate (EGCG) with cefotaxime against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli. PLoS ONE. 2012. doi:10.​1371/​journal.​pone.​0048880.
11.
go back to reference Stapleton PD, Shah S, Hamilton-Miller JM, Hara Y, Nagakoa Y, Kumagai A, Uesato S, Taylor PW. Anti-Staphylococcus aureus activity and oxacillin resistance modulating capacity of 3-O-acyl-catechins. Int J Antimicrob Agents. 2004;24:374–80.CrossRefPubMed Stapleton PD, Shah S, Hamilton-Miller JM, Hara Y, Nagakoa Y, Kumagai A, Uesato S, Taylor PW. Anti-Staphylococcus aureus activity and oxacillin resistance modulating capacity of 3-O-acyl-catechins. Int J Antimicrob Agents. 2004;24:374–80.CrossRefPubMed
12.
go back to reference Zhao WH, Hu ZQ, Okubo S, Hara Y, Shimamura T. Mechanism of synergy between epigallocatechin gallate and β-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2001;45(6):1737–42.CrossRefPubMedPubMedCentral Zhao WH, Hu ZQ, Okubo S, Hara Y, Shimamura T. Mechanism of synergy between epigallocatechin gallate and β-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2001;45(6):1737–42.CrossRefPubMedPubMedCentral
13.
go back to reference Su Y, Ma L, Wen Y, Wang H, Zhang S. Studies of the in vitro antibacterial activities of several polyphenols against clinical isolates of methicillin-resistant Staphylococcus aureus. Molecules. 2014;19:12630–9.CrossRefPubMed Su Y, Ma L, Wen Y, Wang H, Zhang S. Studies of the in vitro antibacterial activities of several polyphenols against clinical isolates of methicillin-resistant Staphylococcus aureus. Molecules. 2014;19:12630–9.CrossRefPubMed
14.
go back to reference Betts JW, Murphy C, Kelly SM, Haswell SJ. Minimum inhibitory and bactericidal concentrations of theaflavin and synergistic combinations with epicatechin and quercetin against clinical isolates of Stenotrophomonas maltophilia. J Microbiol Biotechnol Food Sci. 2012;1(5):1250–8. Betts JW, Murphy C, Kelly SM, Haswell SJ. Minimum inhibitory and bactericidal concentrations of theaflavin and synergistic combinations with epicatechin and quercetin against clinical isolates of Stenotrophomonas maltophilia. J Microbiol Biotechnol Food Sci. 2012;1(5):1250–8.
15.
go back to reference Betts JW, Kelly SM, Haswell SJ. Antibacterial effects of theaflavin and synergy with epicatechin against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. Int J Antimicrob Agents. 2011;38:421–5.CrossRefPubMed Betts JW, Kelly SM, Haswell SJ. Antibacterial effects of theaflavin and synergy with epicatechin against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. Int J Antimicrob Agents. 2011;38:421–5.CrossRefPubMed
16.
go back to reference Tsai CJ, Loh JM, Proft T. Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing. Virulence. 2017;7(3):214–29.CrossRef Tsai CJ, Loh JM, Proft T. Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing. Virulence. 2017;7(3):214–29.CrossRef
17.
go back to reference Hornsey M, Ellington MJ, Doumith M, Thomas CP, Gordon NC, Wareham DW, Quinn J, Lolans K, Livermore DM, Woodford N. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother. 2010;65(8):1589–93.CrossRefPubMed Hornsey M, Ellington MJ, Doumith M, Thomas CP, Gordon NC, Wareham DW, Quinn J, Lolans K, Livermore DM, Woodford N. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother. 2010;65(8):1589–93.CrossRefPubMed
18.
go back to reference Hall MJ, Middleton RF, Westmacott D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother. 1983;11:427–33.CrossRefPubMed Hall MJ, Middleton RF, Westmacott D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother. 1983;11:427–33.CrossRefPubMed
19.
go back to reference Karlowsky JA, Hoban DJ, Zhanel GG, Goldstein BP. In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. Int J Antimicrob Agents. 2006;27(2):174–7.CrossRefPubMed Karlowsky JA, Hoban DJ, Zhanel GG, Goldstein BP. In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. Int J Antimicrob Agents. 2006;27(2):174–7.CrossRefPubMed
20.
go back to reference Hornsey M, Loman N, Wareham DW, Ellington MJ, Pallen MJ, Turton JF, Underwood A, Gaulton T, Thomas CP, Doumith M, Livermore DM, Woodford N. Whole-genome sequencing of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy. J Antimicrob Chemother. 2011;66(7):1499–503.CrossRefPubMed Hornsey M, Loman N, Wareham DW, Ellington MJ, Pallen MJ, Turton JF, Underwood A, Gaulton T, Thomas CP, Doumith M, Livermore DM, Woodford N. Whole-genome sequencing of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy. J Antimicrob Chemother. 2011;66(7):1499–503.CrossRefPubMed
21.
go back to reference Hornsey MA, Wareham DW. In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2011;55(7):3534–7.CrossRefPubMedPubMedCentral Hornsey MA, Wareham DW. In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2011;55(7):3534–7.CrossRefPubMedPubMedCentral
22.
go back to reference Ozdal T, Capanoglu E, Altay FL. A review on protein–phenolic interactions and associated changes. Food Res Int. 2013;51(2):954–70.CrossRef Ozdal T, Capanoglu E, Altay FL. A review on protein–phenolic interactions and associated changes. Food Res Int. 2013;51(2):954–70.CrossRef
23.
go back to reference Spencer JE, Chaudry F, Pannala AS, Srai SK, Debnam E, Rice EC. Decomposition of cocoa procyanidians in the gastric milieu. Biochem Biophys Res Comm. 2000;272(1):236–41.CrossRefPubMed Spencer JE, Chaudry F, Pannala AS, Srai SK, Debnam E, Rice EC. Decomposition of cocoa procyanidians in the gastric milieu. Biochem Biophys Res Comm. 2000;272(1):236–41.CrossRefPubMed
24.
go back to reference Betts JW, Wareham DW. In vitro activity of curcumin in combination with epigallocatechin gallate (EGCG) versus multidrug-resistant Acinetobacter baumannii. BMC Microbiol. 2014;14:172.CrossRefPubMedPubMedCentral Betts JW, Wareham DW. In vitro activity of curcumin in combination with epigallocatechin gallate (EGCG) versus multidrug-resistant Acinetobacter baumannii. BMC Microbiol. 2014;14:172.CrossRefPubMedPubMedCentral
26.
go back to reference Lee KM, Kim WS, Lim J, Nam S, Youn M, Nam SW, Kim Y, Kim SH, Park W, Park S. Antipathogenic properties of green tea polyphenol epigallocatechin gallate at concentrations below the MIC against Enterohemorrhagic Escherichia coli O157:H7. J Food Protect. 2009;72(2):325–33.CrossRef Lee KM, Kim WS, Lim J, Nam S, Youn M, Nam SW, Kim Y, Kim SH, Park W, Park S. Antipathogenic properties of green tea polyphenol epigallocatechin gallate at concentrations below the MIC against Enterohemorrhagic Escherichia coli O157:H7. J Food Protect. 2009;72(2):325–33.CrossRef
Metadata
Title
In vitro and In vivo Activity of Theaflavin–Epicatechin Combinations versus Multidrug-Resistant Acinetobacter baumannii
Authors
Jonathan W. Betts
Michael Hornsey
David W. Wareham
Roberto M. La Ragione
Publication date
01-09-2017
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 3/2017
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-017-0161-2

Other articles of this Issue 3/2017

Infectious Diseases and Therapy 3/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.